Multicenter, double blind, randomized trial to assess the effect of low-dose colchicine
(0.5mg/day) on overall mortality, new coronary syndromes, and ischemic stroke at 2 years
after an acute coronary syndrome. The study hypothesis is that colchicine may reduce the
specified combined endpoint from 16% to 7-8% at a 2-years follow-up.